The article offers information on the findings of a study conducted by researchers from the University of Leicester in Great Britain, which found out that mid-regional pro-adrenomedullin (sAM) levels can predict mortality or heart failure in non-ST-elevation myocardial infarction (NSTEMI) patients.
Processing Request
No Comments.